Daily Brief Health Care: Divi’s Laboratories, Hexagon Nutrition, Oura, Abbott Laboratories, GRAIL, Intuitive Surgical, Eisai Co Ltd, Becton Dickinson and Co, Edwards Lifesciences and more

• Novo committed to scale oral Wegovy manufacturing tenfold by 2030, opening potential peptide overflow work for integrated Indian CDMOs such as Divi’s.
• Oral semaglutide is far more peptide-intensive per patient than injectable Wegovy, so capacity scale-up raises demand for fragments, building blocks and cost-efficient CDMO supply.
• Treat oral Wegovy as optionality only; Lilly tirzepatide remains Divi’s core peptide opportunity, and Divi’s stays our top India Pharma pick.

• Hexagon Nutrition Limited (HEXAGON IN) is a differentiated, research-driven pure-play nutraceutical and clinical nutrition manufacturer operating across three core pillars: Micronutrient Premixes, Branded Clinical & Wellness Nutrition, and Therapeutic Malnutrition Formulations.
• Financial performance has demonstrated strong operating leverage, with revenue growing from INR 2,974.52M in 2024 to INR 3,826.28M in 2026 (a 13.42% 2-year CAGR) and net profit expanding over 3x from INR 122.89M to INR 379.37M, supported by a 1,314 bps expansion in gross margin to 32.15%.
• Trading at an attractive valuation relative to broader healthcare and wellness peers, Hexagon is positioned to capitalize on structural tailwinds including mandatory food fortification policies, expanding clinical nutrition adoption in acute/chronic care, and international expansion across emerging markets.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Oura is an always-on health intelligence platform transforming how people understand and manage health. Its Oura Ring captures biometric data, offering a recurring membership for personalized health insights.
• Oura had 5.0 million Paid Members and approximately 85% 12-Month Paid Member Retention as of June 30, 2026. Revenue was $1,214.5 million.
• Total revenue was $1,214,506 and net income was $60,768 for the nine months ended June 30, 2026. Total stockholders’ deficit was $(1,617,734).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Abbott’s second quarter of 2026 results showed a 4.8% comparable sales growth, marking an acceleration from the previous two quarters, alongside adjusted earnings per share (EPS) of $1.31 which surpassed both the midpoint of company guidance and consensus estimates.
• Management reaffirmed full-year guidance with expected comparable sales growth of 6.5% to 7.5% and raised the EPS range to $5.45–$5.60.
• The company highlighted progress in its product pipeline, including enrollment completion in the TECTONIC coronary IVL trial, an FDA submission for the Amulet 360 device, and obtaining CE Mark for Libre Duo, a dual glucose-ketone sensor.

• GRAIL suddenly became one of healthcare’s most closely watched stocks after its shares surged nearly 34% to $107.97 on September 21, following FDA briefing documents that raised investor expectations ahead of a September 23 advisory committee review of Galleri.
• The blood test searches for cancer-associated DNA methylation patterns and is designed to detect signals from more than 50 types of cancer using a single blood draw, while also predicting where a detected signal may have originated.
• FDA reviewers reportedly raised no major outstanding concerns around analytical performance, study design, or primary safety, although the agency is asking outside experts to consider whether Galleri’s performance supports calling it an “early detection” test.

• Intuitive Surgical reported a solid second quarter in 2026 with several positive operational and financial indicators, alongside some market-specific challenges reflective of broader healthcare dynamics.
• The company saw total procedure volume increase by 16%, including a 15% growth in da Vinci system procedures and a 36% rise in Ion platform procedures.
• The global installed base expanded by 12% for da Vinci systems and 21% for Ion systems, totaling nearly 13,000 systems worldwide by quarter-end.

• Eisai Co Ltd (4523 JP) shares advanced ~30% from June lows. Stronger-than-expected Q1FY27 financial result and value maximization initiatives of Leqembi are mainly driving the shares. 
• Eisai has reported better-than-anticipated Q1FY27 result, with revenue and operating profit reaching 27% and 35% of FY27 full-year forecast, driven by the strong performance 3L major products and favorable Fx.
• In near-term, Eisai’s growth will be Leqembi centered. For FY27, Eisai has guided for Leqembi revenue of ¥144B (up 64% YoY), supported by Leqembi Iqlik and blood-based biomarker (BBM).

• Becton, Dickinson and Company reported a third-quarter fiscal 2026 revenue of $5 billion, reflecting a 4.4% increase on a foreign exchange-neutral basis and driven by broad-based growth across over 90% of its portfolio.
• Key growth was observed in biologic drug delivery, advanced patient monitoring, PureWick, advanced tissue regeneration, peripheral vascular disease, and pharmacy automation through the Rowa platform.
• U.S. Medical Diagnostic Systems (MDS) and Specimen Management showed strong performance fueled by utilization recovery and share gains, partially offset by expected headwinds in Alaris and vaccine sales in China.

• Edwards Lifesciences reported stronger-than-expected second quarter 2026 financial results, delivering total sales growth of 12.5% year-over-year to $1.74 billion, underpinned by broad-based performance across its structural heart therapy portfolio and geographical regions.
• The company raised its full-year sales guidance to 10% to 11%, reflecting confidence in sustained demand and the strength of multiple growth drivers, while reaffirming its adjusted earnings per share (EPS) guidance within the prior range of $2.95 to $3.05.
• The transcatheter aortic valve replacement (TAVR) segment generated $1.3 billion in sales, increasing 10.5% year-over-year and benefiting from procedural growth, market expansion through new clinical evidence, and the exit of a major competitor in the prior-year quarter.